Tenet Healthcare Corporation THC
Composite 60/100; the shares have moved about 46% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Growth ranks 34/100 — a moderate mark against it.
Valuation ranks 77/100 — a strong point in its favour. Momentum ranks 71/100 — a moderate point in its favour. Quality ranks 69/100 — a moderate point in its favour.
Growth ranks 34/100 — a moderate mark against it. Balance-sheet strength ranks 47/100 — a slight mark against it.
What the company does Tenet Healthcare (THC) operates general and specialty hospitals and ambulatory care centers across the U.S., providing acute care, surgical services, diagnostics, and outpatient procedures including orthopedics, cardiology, and transplants.
Key financials THC posts strong returns: ROE 37.3%, ROA 8.3%, ROCE 16.6%. Margins are healthy (gross 41.7%, operating 18.2%, net 10.3%) with revenue growth 6.8% and EPS growth 213.4%. Leverage is elevated (Debt/Equity 1.52, Net debt/EBITDA 2.30) but interest coverage is 5.08.
Stock health Sideravia scores THC 64.7 overall, flagging strong quality (65.6) and valuation (72.6) but weak strength (46.8). Momentum is robust (3m 40.33%, 6m 33.31%, 12m 61.94%) with RSI 73.00.
Price vs fair value The stock trades at a discount to both our fair-value estimate and the analyst target. - Discount of 8.60% versus our fair-value estimate of 274.46 (Sideravia) - Discount of 9.79% versus the 12-month target of 277.48 based on 21 analysts (Zacks) - Recent headlines highlight rising uninsured patient volumes pressuring hospitals (WSJ), while multiple Zacks articles cite investor interest, growth appeal, and momentum reasons for the valuation gap.
Looking forward Forward P/E of 13.81 and EV/EBITDA of 5.59 suggest valuation support, but high leverage and weak strength score warrant caution. Momentum and quality metrics remain supportive unless uninsured care trends deteriorate further.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.